Astria Therapeutics (NASDAQ:ATXS) Stock Price Down 4.1%

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) traded down 4.1% during mid-day trading on Wednesday . The stock traded as low as $10.96 and last traded at $10.96. 4,053 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 678,856 shares. The stock had previously closed at $11.43.

Analysts Set New Price Targets

A number of equities research analysts have commented on ATXS shares. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. TD Cowen began coverage on Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 target price on the stock. Oppenheimer boosted their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a research note on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Friday, September 27th. Finally, Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Astria Therapeutics presently has an average rating of “Buy” and an average price target of $25.20.

Astria Therapeutics Stock Up 2.3 %

The stock has a market cap of $641.93 million, a P/E ratio of -4.93 and a beta of 0.71. The firm has a 50 day moving average price of $11.31 and a 200 day moving average price of $10.75.

Astria Therapeutics (NASDAQ:ATXS) last released its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Equities analysts predict that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares during the period. ADAR1 Capital Management LLC purchased a new position in Astria Therapeutics during the fourth quarter valued at $1,469,000. Tidal Investments LLC bought a new stake in Astria Therapeutics in the 1st quarter valued at $1,664,000. Perceptive Advisors LLC lifted its stake in Astria Therapeutics by 82.9% in the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after purchasing an additional 1,814,608 shares in the last quarter. Finally, Sofinnova Investments Inc. bought a new position in shares of Astria Therapeutics during the 2nd quarter valued at about $552,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.